RxCelerate, recently acquired Total Scientific in May 2018, is an outsourced drug discovery and development platform. Our experienced team design and deliver on integrated programs to drive your asset or project through drug discovery, preclinical research to clinical proof-of-concept.

We specialise in bespoke experimental design with data-rich endpoints; maximising your chances of reaching the clinic. We optimise translation from preclinical research to clinical studies by the early integration of mechanism-validation and biomarker-development into preclinical pharmacology strategies.

One of our main experience is in all aspects of biomarker research, from biomarker identification using ‘omics technology through assay design, development and validation to multi-site clinical studies designed to validate or test biomarkers.

In addition to the above biomarker related activities, we also provide a wide range of in vitro laboratory services including:
Biacore (SPR) to study the real time binding of two molecules.
Multiplex assays, using Luminex technology.
Enzyme and binding assays.
Mass Spectrometry – LC-MS/MS
Data management and biostatistics.
GLP / GxP

We also like to think that our honest, flexible and bespoke approach means that we are often one of the first CROs our clients turn to for something a bit different, whether that is plugging a gap in a project plan or a complete development project.

Our clients include biotech, virtual or early stage start-ups, diagnostics and universities.